JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
142.88
+0.90 (+0.63%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close141.98
Open142.18
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range141.69 - 143.13
52 Week Range118.62 - 148.32
Volume13,283,427
Avg. Volume6,112,773
Market Cap383.313B
Beta0.53
PE Ratio (TTM)284.06
EPS (TTM)0.50
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2018-08-27
1y Target Est143.85
Trade prices are not sourced from all markets
  • Barrons.com12 hours ago

    Boston Scientific, Edwards Lifesciences May Tempt J&J

    Either device maker could be a rewarding acquisition for the old-line pharma and consumer-product company

  • Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
    PR Newswire15 hours ago

    Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

    Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression TITUSVILLE, N.J. , Sept. 21, 2018 /PRNewswire/ -- The ...

  • How Does Sage Therapeutics’ Product Portfolio Look in September?
    Market Realist19 hours ago

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

  • Is Abbott Laboratories Trading at a High Valuation in September?
    Market Realistyesterday

    Is Abbott Laboratories Trading at a High Valuation in September?

    On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.

  • Abbott Laboratories’ 379th Consecutive Quarterly Dividend
    Market Realistyesterday

    Abbott Laboratories’ 379th Consecutive Quarterly Dividend

    On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.

  • CNBC2 days ago

    'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus

    CNBC's Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis. Cohen says that his small pharmaceutical company is beating big pharma when it comes to these treatments.

  • 7 Dow Jones Stocks Leading the Push to New Highs
    InvestorPlace2 days ago

    7 Dow Jones Stocks Leading the Push to New Highs

    The Dow Jones Industrial Average finally pushed above its January record high on Thursday, ending a year-long consolidation range that was spurred by worries over higher interest rates, Federal Reserve policy tightening and the fallout from President Trump’s trade war.

  • Here’s a clear case for owning dividend stocks instead of bonds
    MarketWatch2 days ago

    Here’s a clear case for owning dividend stocks instead of bonds

    Hank Smith, co-chief investment officer of Haverford Trust, has laid out a clear case for dividend stocks over bonds. Pepsi’s stock had a dividend yield of 3.25% as of the close on Sept. 18, while 10-year U.S. Treasury paper yielded 3.05%.

  • Analysts Are Overwhelmingly Bullish on Abbott Laboratories
    Market Realist2 days ago

    Analysts Are Overwhelmingly Bullish on Abbott Laboratories

    Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.

  • Lake Nona appears set to land big biotech facility
    American City Business Journals2 days ago

    Lake Nona appears set to land big biotech facility

    Before dirt even has been tossed, a future biotech manufacturing plant in Lake Nona’s 650-acre Medical City is dreaming up expansion plans. The 18-acre site — likely slated for Cranbury, N.J.-based global tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) — already is being considered for a planned development with manufacturing, office and warehouse space. Real estate sources said Amicus likely is the company behind Project Olympus.

  • What Quest Diagnostics’ Valuation Trend Indicates
    Market Realist2 days ago

    What Quest Diagnostics’ Valuation Trend Indicates

    In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.

  • Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates
    Market Realist2 days ago

    Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates

    Merck & Co. reported a rise of 5% in its top line to ~$10.5 billion in the second quarter, including a 4% rise in operating revenue and a 1% favorable impact of foreign exchange. This revenue growth was driven by the strong sales of Keytruda, the Gardasil franchise, ProQuad/Varivax, RotaTeq, Pneumovax 23, Bridion, Noxafil, Simponi, Belsomra, Isentress, Januvia, Janumet, Atozet, Adempas, and a few other drugs from its pharmaceutical business.

  • Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
    PR Newswire3 days ago

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Taking Stock of Quest Diagnostics’ Recent Acquisitions
    Market Realist3 days ago

    Taking Stock of Quest Diagnostics’ Recent Acquisitions

    Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.

  • How Quest Diagnostics Is Positioned in 2018
    Market Realist3 days ago

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.

  • J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
    Zacks3 days ago

    J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

    Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 18.) Boston Scientific Corporation (NYSE: BSX ) Cara Therapeutics ...

  • MarketWatch4 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • Reuters4 days ago

    Exclusive - India, U.S. closing in on package deal to remove trade irritants

    Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said. Having skirmished for months over tit-for-tat tariffs on steel and some agricultural products, the two sides began talks in June that also cover India's concerns over U.S. steel tariffs and U.S. problems with Indian tariffs on imported IT equipment. U.S. President Donald Trump, who dislikes multilateral trade agreements, said earlier this month that India had approached the United States to "start doing a trade deal," without giving any details.

  • InvestorPlace4 days ago

    Cronos Gets Bigger As It Partners With Ginkgo Bioworks

    From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.

  • Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
    Zacks5 days ago

    Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

    Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

  • Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
    Zacks5 days ago

    Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

    Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

  • J&J Talc Supplier Takes No Chances on Another Big Jury Loss
    Bloomberg5 days ago

    J&J Talc Supplier Takes No Chances on Another Big Jury Loss

    Imerys SA, which supplies talc to Johnson & Johnson, isn’t taking chances as another jury weighs whether to sock the health-care giant with a punishing verdict. A unit of Imerys agreed to settle its part of a California woman’s lawsuit blaming both companies for causing her cancer with asbestos-tainted talc at the conclusion of a four-week state-court trial in Pasadena, just before the case was sent to jury for deliberations. In July, a St. Louis jury ordered J&J to pay $4.69 billion in damages to 22 women who blamed their ovarian cancer on exposure to asbestos in the company’s powders.

  • Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
    Zacks5 days ago

    Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

    Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.